A de novo substructure generation algorithm for identifying the privileged chemical fragments of liver X receptorβ agonists
- PMID: 28894088
- PMCID: PMC5593923
- DOI: 10.1038/s41598-017-08848-4
A de novo substructure generation algorithm for identifying the privileged chemical fragments of liver X receptorβ agonists
Abstract
Liver X receptorβ (LXRβ) is a promising therapeutic target for lipid disorders, atherosclerosis, chronic inflammation, autoimmunity, cancer and neurodegenerative diseases. Druggable LXRβ agonists have been explored over the past decades. However, the pocket of LXRβ ligand-binding domain (LBD) is too large to predict LXRβ agonists with novel scaffolds based on either receptor or agonist structures. In this paper, we report a de novo algorithm which drives privileged LXRβ agonist fragments by starting with individual chemical bonds (de novo) from every molecule in a LXRβ agonist library, growing the bonds into substructures based on the agonist structures with isomorphic and homomorphic restrictions, and electing the privileged fragments from the substructures with a popularity threshold and background chemical and biological knowledge. Using these privileged fragments as queries, we were able to figure out the rules to reconstruct LXRβ agonist molecules from the fragments. The privileged fragments were validated by building regularized logistic regression (RLR) and supporting vector machine (SVM) models as descriptors to predict a LXRβ agonist activities.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures


















Similar articles
-
Predicting selective liver X receptor β agonists using multiple machine learning methods.Mol Biosyst. 2015 May;11(5):1241-50. doi: 10.1039/c4mb00718b. Mol Biosyst. 2015. PMID: 25734698
-
Identifying selective agonists targeting LXRβ from terpene compounds of alismatis rhizoma.J Mol Model. 2021 Feb 22;27(3):91. doi: 10.1007/s00894-021-04699-z. J Mol Model. 2021. PMID: 33616795
-
Structurally Selective Mechanism of Liver X Receptor Ligand: In Silico and In Vitro Studies.J Chem Inf Model. 2019 Jul 22;59(7):3277-3290. doi: 10.1021/acs.jcim.9b00292. Epub 2019 Jun 26. J Chem Inf Model. 2019. PMID: 31192592
-
Ligands of Therapeutic Utility for the Liver X Receptors.Molecules. 2017 Jan 5;22(1):88. doi: 10.3390/molecules22010088. Molecules. 2017. PMID: 28067791 Free PMC article. Review.
-
Design, structure activity relationships and X-Ray co-crystallography of non-steroidal LXR agonists.Curr Med Chem. 2008;15(2):195-209. doi: 10.2174/092986708783330584. Curr Med Chem. 2008. PMID: 18220775 Review.
Cited by
-
Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches.Molecules. 2018 Jun 4;23(6):1349. doi: 10.3390/molecules23061349. Molecules. 2018. PMID: 29867043 Free PMC article.
-
LSA: a local-weighted structural alignment tool for pharmaceutical virtual screening.RSC Adv. 2019 Jan 29;9(7):3912-3917. doi: 10.1039/c8ra08915a. eCollection 2019 Jan 25. RSC Adv. 2019. PMID: 35518105 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous